Table 2.
Baseline clinical characteristics.
| Variables | Intervention group (n = 42) | Control group (n = 42) | p value | |
|---|---|---|---|---|
| Gender | Male | 31 | 27 | 0.345 |
| Female | 11 | 15 | ||
|
| ||||
| Age (years) | 65.24 ± 8.96 | 65.36 ± 8.82 | 0.951 | |
|
| ||||
| Comorbidity | Diabetes | 2 | 1 | 0.168 |
| Hypertension | 24 | 25 | ||
| Hyperlipidemia | 4 | 1 | ||
| Two of the above | 0 | 3 | ||
| None | 12 | 12 | ||
|
| ||||
| Heparin (U) | 4940.48 ± 938.36 | 5285.71 ± 918.26 | 0.092 | |
|
| ||||
| Heart stent | None | 38 | 39 | 0.898 |
| One | 3 | 2 | ||
| Two | 1 | 1 | ||
|
| ||||
| APTT | 36.74 ± 3.69 | 36.67 ± 3.82 | 0.938 | |
| PT | 13.12 ± 2.05 | 12.79 ± 0.58 | 0.322 | |
| INR | 1.03 ± 0.23 | 0.99 ± 0.07 | 0.306 | |
| Thrombocytes | 186.72 ± 45.83 | 184.38 ± 39.06 | 0.802 | |
APTT: activated partial thromboplastin time; PT: prothrombin time; INR: international normalized ratio.